256 related articles for article (PubMed ID: 22134373)
1. Adenosine A2A-receptor antagonism and pathophysiology of Parkinson's disease and drug-induced movement disorders.
Kulisevsky J; Poyurovsky M
Eur Neurol; 2012; 67(1):4-11. PubMed ID: 22134373
[TBL] [Abstract][Full Text] [Related]
2. Role of adenosine A2A receptors in parkinsonian motor impairment and l-DOPA-induced motor complications.
Morelli M; Di Paolo T; Wardas J; Calon F; Xiao D; Schwarzschild MA
Prog Neurobiol; 2007 Dec; 83(5):293-309. PubMed ID: 17826884
[TBL] [Abstract][Full Text] [Related]
3. Conditional neural knockout of the adenosine A(2A) receptor and pharmacological A(2A) antagonism reduce pilocarpine-induced tremulous jaw movements: studies with a mouse model of parkinsonian tremor.
Salamone JD; Collins-Praino LE; Pardo M; Podurgiel SJ; Baqi Y; Müller CE; Schwarzschild MA; Correa M
Eur Neuropsychopharmacol; 2013 Aug; 23(8):972-7. PubMed ID: 22947264
[TBL] [Abstract][Full Text] [Related]
4. Mode of action of adenosine A2A receptor antagonists as symptomatic treatment for Parkinson's disease.
Mori A
Int Rev Neurobiol; 2014; 119():87-116. PubMed ID: 25175962
[TBL] [Abstract][Full Text] [Related]
5. [Is the inhibition of adenosine A(2A) receptors an efficient way of Parkinson's disease treatment?].
Ceiślak M; Komoszyński M
Neurol Neurochir Pol; 2006; 40(3):219-26. PubMed ID: 16794962
[TBL] [Abstract][Full Text] [Related]
6. Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.
Calon F; Dridi M; Hornykiewicz O; Bédard PJ; Rajput AH; Di Paolo T
Brain; 2004 May; 127(Pt 5):1075-84. PubMed ID: 15033896
[TBL] [Abstract][Full Text] [Related]
7. Adenosine A2A receptors and Parkinson's disease.
Morelli M; Carta AR; Jenner P
Handb Exp Pharmacol; 2009; (193):589-615. PubMed ID: 19639294
[TBL] [Abstract][Full Text] [Related]
8. Effects of the selective adenosine A2A receptor antagonist, SCH 412348, on the parkinsonian phenotype of MitoPark mice.
Smith KM; Browne SE; Jayaraman S; Bleickardt CJ; Hodge LM; Lis E; Yao L; Rittle SL; Innocent N; Mullins DE; Boykow G; Reynolds IJ; Hill D; Parker EM; Hodgson RA
Eur J Pharmacol; 2014 Apr; 728():31-8. PubMed ID: 24486705
[TBL] [Abstract][Full Text] [Related]
9. Striatal plasticity at the network level. Focus on adenosine A2A and D2 interactions in models of Parkinson's Disease.
Tanganelli S; Sandager Nielsen K; Ferraro L; Antonelli T; Kehr J; Franco R; Ferré S; Agnati LF; Fuxe K; Scheel-Krüger J
Parkinsonism Relat Disord; 2004 Jul; 10(5):273-80. PubMed ID: 15196505
[TBL] [Abstract][Full Text] [Related]
10. Potent and selective adenosine A(2A) receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones.
Harris JM; Neustadt BR; Zhang H; Lachowicz J; Cohen-Williams M; Varty G; Hao J; Stamford AW
Bioorg Med Chem Lett; 2011 Apr; 21(8):2497-501. PubMed ID: 21398125
[TBL] [Abstract][Full Text] [Related]
11. Adenosine A(2A) receptors, dopamine D(2) receptors and their interactions in Parkinson's disease.
Fuxe K; Marcellino D; Genedani S; Agnati L
Mov Disord; 2007 Oct; 22(14):1990-2017. PubMed ID: 17618524
[TBL] [Abstract][Full Text] [Related]
12. [The treatment of Parkinson's disease--adenosine A2A receptor antagonists].
Matsubara E; Shoji M; Abe K
Nihon Rinsho; 2002 Jan; 60(1):112-6. PubMed ID: 11808320
[TBL] [Abstract][Full Text] [Related]
13. A2A adenosine receptor overexpression and functionality, as well as TNF-alpha levels, correlate with motor symptoms in Parkinson's disease.
Varani K; Vincenzi F; Tosi A; Gessi S; Casetta I; Granieri G; Fazio P; Leung E; MacLennan S; Granieri E; Borea PA
FASEB J; 2010 Feb; 24(2):587-98. PubMed ID: 19776336
[TBL] [Abstract][Full Text] [Related]
14. Adenosine, adenosine A 2A antagonists, and Parkinson's disease.
Jenner P; Mori A; Hauser R; Morelli M; Fredholm BB; Chen JF
Parkinsonism Relat Disord; 2009 Jul; 15(6):406-13. PubMed ID: 19446490
[TBL] [Abstract][Full Text] [Related]
15. Novel therapy in Parkinson's disease: adenosine A(2A) receptor antagonists.
Szabó N; Kincses ZT; Vécsei L
Expert Opin Drug Metab Toxicol; 2011 Apr; 7(4):441-55. PubMed ID: 21332415
[TBL] [Abstract][Full Text] [Related]
16. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
Pinna A; Pontis S; Borsini F; Morelli M
Synapse; 2007 Aug; 61(8):606-14. PubMed ID: 17476684
[TBL] [Abstract][Full Text] [Related]
17. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
[TBL] [Abstract][Full Text] [Related]
18. An overview of adenosine A2A receptor antagonists in Parkinson's disease.
Jenner P
Int Rev Neurobiol; 2014; 119():71-86. PubMed ID: 25175961
[TBL] [Abstract][Full Text] [Related]
19. Novel neuroprotection by caffeine and adenosine A(2A) receptor antagonists in animal models of Parkinson's disease.
Kalda A; Yu L; Oztas E; Chen JF
J Neurol Sci; 2006 Oct; 248(1-2):9-15. PubMed ID: 16806272
[TBL] [Abstract][Full Text] [Related]
20. An update on adenosine A2A receptors as drug target in Parkinson's disease.
Vallano A; Fernandez-Duenas V; Pedros C; Arnau JM; Ciruela F
CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):659-69. PubMed ID: 21838670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
